Skip to ContentSkip to Navigation
About us Latest news News News articles

Novel asymmetric copper-catalyzed transformations

19 March 2012

PhD ceremony: Mr. P.H. Bos, 14.30 uur, Academiegebouw, Broerstraat 5, Groningen

Dissertation: Novel asymmetric copper-catalyzed transformations

Promotor(s): prof. B.L. Feringa

Faculty: Mathematics and Natural Sciences

As a consequence of the increased complexity of target molecules both in industry and academic research, the development of new methodology remains an important aspect of organic chemistry both in current time as well as for the future. Across the entire field of chemistry, from material science to pharmaceutical chemistry, efficient synthetic methods are crucial and of increasing importance, especially in the context of sustainable chemistry for the future. This thesis describes the development of a variety of novel asymmetric carbon-carbon bond forming reactions. All of the methods that were developed in this thesis rely on the use of catalytic amounts of chiral copper/ligand complexes in combination with organometallic reagents to establish asymmetric carbon-carbon bond formation with excellent enantiomeric excess.

Last modified:13 March 2020 01.00 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 17 July 2025

    Veni-grants for eleven UG researchers

    The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to eleven researchers of the University of Groningen and the UMCG: Quentin Changeat, Wen Wu, Femke Cnossen, Stacey Copeland, Bart Danon, Gesa Kübek, Hannah Laurens, Adi...

  • 14 July 2025

    ERC Proof of Concept grant for Kottapalli and Covi

    Professors Ajay Kottapalli and Erika Covi have received Proof of Concept grants from the European Research Council (ERC).

  • 10 July 2025

    Dutch Research Agenda funding for nanomedicine research

    Prof Dr Anna Salvati, Dr Christoffer Åberg and Prof Dr Siewert-Jan Marrink have been granted a National Science Agenda (NWA) funding to further develop life-saving drugs based on nanotechnology with the NanoMedNL consortium.